A Mission to Increase Healthy Lifespan with MBTs
Our mission is to increase healthy lifespan by treating diseases of aging with underlying metabolic dysfunction and comorbidities. CohBar's MBTs represent an emerging class of drugs for the treatment of age-related diseases. They originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. The founder's discoveries resulted from more than 15 years of research supported by more than $30 million in grants to their academic institutions.